Update on N6‐methyladenosine methylation in obesity‐related diseases

C Cheng, F Yu, G Yuan, J Jia - Obesity, 2024 - Wiley Online Library
Obesity is a chronic metabolic disease that is closely related to type 2 diabetes mellitus,
cardiovascular diseases, nonalcoholic fatty liver disease, obstructive sleep apnea, and …

[HTML][HTML] Roles of RNA methylations in cancer progression, autophagy, and anticancer drug resistance

H Jo, K Shim, D Jeoung - International Journal of Molecular Sciences, 2023 - mdpi.com
RNA methylations play critical roles in RNA processes, including RNA splicing, nuclear
export, nonsense-mediated RNA decay, and translation. Regulators of RNA methylations …

Research progress of human key DNA and RNA methylation-related enzymes assay

T Ma, Q Zhang, S Zhang, D Yue, F Wang, Y Ren… - Talanta, 2024 - Elsevier
Gene methylation-related enzymes (GMREs) are disfunction and aberrantly expressed in a
variety of cancers, such as lung, gastric, and pancreatic cancers and have important …

[HTML][HTML] Dissecting the effects of METTL3 on alternative splicing in prostate cancer

L Wang, L Shi, Y Liang, JKW Ng, CH Yin… - Frontiers in …, 2023 - frontiersin.org
Although the role of METTL3 has been extensively studied in many cancers, its role in
isoform switching in prostate cancer (PCa) has been poorly explored. To investigate its role …

[HTML][HTML] The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target

X Zhou, K Chai, H Zhu, C Luo, X Zou, J Zou, G Zhang - BMC cancer, 2024 - Springer
The incidence of prostate cancer (PCa), the most prevalent malignancy, is currently at the
forefront. RNA modification is a subfield of the booming field of epigenetics. To date, more …

[HTML][HTML] The role of RNA modification in urological cancers: mechanisms and clinical potential

X Zhou, H Zhu, C Luo, Z Yan, G Zheng, X Zou, J Zou… - Discover Oncology, 2023 - Springer
RNA modification is a post-transcriptional level of regulation that is widely distributed in all
types of RNAs, including mRNA, tRNA, rRNA, miRNA, and lncRNA, where N6 …

[HTML][HTML] METTL3 inhibitor suppresses the progression of prostate cancer via IGFBP3/AKT pathway and synergizes with PARP inhibitor

X Chen, M Wang, H Wang, J Yang, X Li… - Biomedicine & …, 2024 - Elsevier
The RNA N 6-methyladenosine (m6A) regulator METTL3 is an important regulatory gene in
various progressive processes of prostate cancer (PCa). METTL3 inhibitors have been …

[HTML][HTML] The m6A regulators in prostate cancer: molecular basis and clinical perspective

Y Cao, M Jia, C Duan, Z Yang, B Cheng… - Frontiers in …, 2024 - frontiersin.org
Prostate cancer (PCa) is the second leading cause of cancer-related death among men in
western countries. Evidence has indicated the significant role of the androgen receptor (AR) …

[HTML][HTML] Epitranscriptomic mechanisms of androgen signalling and prostate cancer

R Patke, AE Harris, CL Woodcock, R Thompson… - Neoplasia, 2024 - Elsevier
Prostate cancer (PCa) is the second most common cancer diagnosed in men. While radical
prostatectomy and radiotherapy are often successful in treating localised disease, post …

RNA N6-methyladenosine modifications in urological cancers: from mechanism to application

L Yang, J Ying, Q Tao, Q Zhang - Nature Reviews Urology, 2024 - nature.com
Abstract The N6‐methyladenosine (m6A) modification is the most common modification of
messenger RNAs in eukaryotes and has crucial roles in multiple cancers, including in …